Hospital
Plantation General Hospital LP
Plantation General Hospital LP was paid $8.65M by Medicaid between Jan 2018 and Dec 2024, across 179 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoPLANTATION GENERAL HOSPITAL LP
MIAMI, FL 33133
MIAMI, FL 33133
33aNPI1023387479assigned 12/14/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.65M
24GClaims467,308
24DCodes billed179
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#58 of 163
Median peer was paid$4.77M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 62,973 | $1.09M | |
| 2019 | 122,367 | $1.28M | |
| 2020 | 64,442 | $821K | |
| 2021 | 69,580 | $1.16M | |
| 2022 | 80,825 | $2.15M | |
| 2023 | 46,706 | $1.52M | |
| 2024incomplete | 20,415 | $636K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 26,340 | 21,300 | $1.87M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 18,416 | 15,862 | $1.46M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 9.2% | 4,903 | 3,896 | $794K |
| 80053 | Comprehensive metabolic panel | 4.7% | 24,484 | 16,968 | $404K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.6% | 4,362 | 3,297 | $395K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 8,375 | 5,527 | $305K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 1,769 | 1,490 | $251K |
| A9270 | Non-covered item or service | 2.8% | 26,444 | 3,601 | $241K |
| G0378 | Hospital observation service, per hour | 2.6% | 9,531 | 4,140 | $227K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 2,358 | 2,117 | $212K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 12,462 | 1,666 | $207K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 1,763 | 1,440 | $188K |
167 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | 1.9% | 9,077 | $167K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 1,211 | $92K |
| 85027 | <1% | 36,548 | $78K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 367 | $77K |
| 86850 | <1% | 2,416 | $68K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 982 | $68K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,864 | $63K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,592 | $58K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,760 | $57K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,143 | $55K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 729 | $53K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,055 | $47K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 972 | $43K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,524 | $41K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 642 | $36K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,232 | $35K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,580 | $34K |
| 84484 | <1% | 11,395 | $32K | |
| 81025 | <1% | 10,220 | $32K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,471 | $31K |
| 85610 | <1% | 8,355 | $30K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,826 | $29K |
| 72131 | <1% | 427 | $29K | |
| 87040 | <1% | 4,128 | $27K | |
| 80047 | <1% | 1,024 | $26K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,577 | $26K |
| 87070 | <1% | 2,145 | $26K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,880 | $25K |
| 76801 | <1% | 1,411 | $25K | |
| 85730 | <1% | 7,626 | $25K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,995 | $24K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,197 | $23K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,404 | $22K |
| 97116 | <1% | 2,189 | $22K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,029 | $21K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,004 | $19K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 694 | $18K |
| 71250 | <1% | 678 | $18K | |
| 82550 | <1% | 6,681 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,799 | $17K |
| 86900 | <1% | 3,153 | $17K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,106 | $16K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,225 | $16K |
| 83735 | <1% | 4,490 | $15K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 847 | $14K |
| 97163 | <1% | 1,161 | $14K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,538 | $14K |
| 93458 | <1% | 70 | $12K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,524 | $12K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,907 | $12K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 872 | $12K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,880 | $11K |
| J1815 | Injection, insulin, per 5 units | <1% | 667 | $10K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,448 | $10K |
| 93971 | <1% | 479 | $10K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 66 | $10K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 963 | $10K |
| 81003 | <1% | 3,863 | $9K | |
| 84702 | <1% | 3,233 | $9K | |
| 93976 | <1% | 296 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,860 | $8K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,632 | $8K |
| 83690 | <1% | 7,172 | $8K | |
| 84100 | <1% | 2,918 | $8K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,086 | $8K |
| 83880 | <1% | 2,735 | $7K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 384 | $7K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 444 | $7K |
| 73564 | <1% | 487 | $7K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 782 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,182 | $7K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 641 | $7K |
| 97162 | <1% | 278 | $7K | |
| 82553 | <1% | 770 | $6K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,149 | $6K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,756 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 952 | $6K |
| 73030 | <1% | 251 | $6K | |
| 86901 | <1% | 3,090 | $6K | |
| 81001 | <1% | 5,629 | $5K | |
| 73630 | <1% | 377 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,370 | $5K |
| C1769 | Guide wire | <1% | 1,102 | $4K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 560 | $4K |
| 80076 | <1% | 1,774 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,492 | $4K |
| 93970 | <1% | 190 | $4K | |
| 36821 | <1% | 38 | $3K | |
| 80061 | Lipid panel | <1% | 1,188 | $3K |
| 83605 | <1% | 4,429 | $3K | |
| 87077 | <1% | 1,064 | $2K | |
| 97167 | <1% | 381 | $2K | |
| 73610 | <1% | 199 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 567 | $2K |
| 87205 | <1% | 200 | $2K | |
| 74018 | <1% | 133 | $2K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 110 | $2K |
| 85379 | <1% | 1,202 | $2K | |
| 87430 | <1% | 2,121 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 25 | $2K |
| 73130 | <1% | 101 | $2K | |
| 82565 | <1% | 77 | $2K | |
| 87807 | <1% | 336 | $2K | |
| 76775 | <1% | 100 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,760 | $1K |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 43 | $1K |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 43 | $1K |
| 76376 | <1% | 231 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 44 | $1K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,273 | $1K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 14 | $958.02 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,556 | $930.67 |
| 87487 | <1% | 143 | $922.50 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,319 | $856.93 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 145 | $832.65 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 468 | $703.92 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 414 | $701.76 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 358 | $656.27 |
| 72100 | <1% | 87 | $618.63 | |
| 93288 | <1% | 70 | $576.84 | |
| 76937 | <1% | 580 | $559.02 | |
| 87275 | <1% | 2,732 | $499.68 | |
| 87276 | <1% | 2,728 | $445.49 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 271 | $424.21 |
| 87210 | <1% | 42 | $391.63 | |
| 87340 | <1% | 20 | $364.52 | |
| 84703 | <1% | 185 | $358.26 | |
| 82803 | <1% | 39 | $350.23 | |
| 70486 | <1% | 29 | $293.41 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 397 | $274.03 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 397 | $237.69 |
| 82247 | <1% | 133 | $227.32 | |
| 86140 | <1% | 185 | $214.75 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 99 | $208.11 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 143 | $191.82 |
| 90714 | <1% | 264 | $187.97 | |
| 76641 | <1% | 20 | $170.22 | |
| 84075 | <1% | 89 | $153.68 | |
| 82040 | <1% | 99 | $153.68 | |
| 84155 | <1% | 89 | $153.68 | |
| 84460 | <1% | 90 | $153.68 | |
| 84450 | <1% | 105 | $153.68 | |
| J3490 | Unclassified drugs | <1% | 136 | $144.36 |
| 85651 | <1% | 272 | $132.19 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 49 | $121.58 |
| 99152 | <1% | 250 | $115.85 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 165 | $101.03 |
| 82077 | <1% | 377 | $62.77 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 65 | $60.76 |
| 84520 | <1% | 34 | $59.84 | |
| 96376 | <1% | 64 | $29.52 | |
| 82248 | <1% | 534 | $23.13 | |
| 83550 | <1% | 14 | $18.43 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 65 | $18.43 |
| 83540 | <1% | 14 | $18.43 | |
| 80320 | <1% | 94 | $18.39 | |
| 82607 | <1% | 19 | $10.05 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 316 | $0.00 |
| 88304 | 0% | 173 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 106 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 30 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 58 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 37 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 313 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 154 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 41 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 46 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWELCH, JOAN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Hca Health Services of New Hampshire, INC. | Derry, NH | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.